Grünenthal GmbH
http://www.grunenthal.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grünenthal GmbH
AZ Sells EU Rights To Former Jewel In The Crown, Crestor
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Adhesys Medical GmbH
- Adhesys Medical Inc.
- Averitas Pharma, Inc.
- Grunenthal GmbH
- Gruenenthal GmbH
- Grunental GmbH
- Inversiones Gruchi S.A.
- Inversiones Gruchi Limitada
- Laboratorios Andrómaco S.A.
- Thar Pharmaceuticals, Inc.